StockNow
Log in
U.S. Markets

Regeneron Pharmaceuticals (REGN) Adj. EPS 14.29 (exp. 10.21), Revenue 4.29bln (exp. 3.82bln)

StockNow breaking-news AI analysis

Regeneron reported record-breaking Q2 2026 results, significantly beating EPS and revenue estimates while achieving all-time high sales for Dupixent, EYLEA HD, and Libtayo.

News detail

Dupixent global net sales(recorded by Sanofi) increased 38% to a new all-time high of USD 6.0bln. EYLEA HD U.S. net sales increased 52% to a new all-time high of USD 596mln. Libtayo global net sales increased 30% to a new all-time high of USD 489mln. Sanofi Development Balance fully repaid as of end of second quarter 2026.

2 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYU.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)

Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement